Screener
Eli Lilly LLY Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:40 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000059478-26-000081
| Assets | June 30, 2026 / (Unaudited) | December 31, 2025 |
|---|---|---|
| Current Liabilities | ||
| Short-term borrowings and current maturities of long-term debt | $7,050 | $1,635 |
| Accounts payable | 6,112 | 5,379 |
| Employee compensation | 1,798 | 2,375 |
| Sales rebates and discounts | 21,122 | 17,382 |
| Other current liabilities | 11,659 | 8,457 |
| Total current liabilities | 47,741 | 35,228 |
| Noncurrent Liabilities |
Item 1. Financial Statements
FAQ
- What is Eli Lilly's accrued expenses?
- Eli Lilly (LLY) reported accrued expenses of $1.8B in Q2 2026.
- How has Eli Lilly's accrued expenses changed year-over-year?
- Eli Lilly's accrued expenses increased by 38.0% year-over-year, from $1.3B to $1.8B.
- What is the long-term trend for Eli Lilly's accrued expenses?
- Over 5 years (2020 to 2025), Eli Lilly's accrued expenses has grown at a 19.0% compound annual growth rate (CAGR), from $997.2M to $2.38B.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Eli Lilly's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude